Stock listing
BOATS:BCAB BioAtla, Inc. Stock
US listing (BOATS) of BioAtla, Inc. · home listing NASDAQ:BCAB
Follow BioAtla, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:BCAB
$1.55 USD +0.26 (+20.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:BCAB
- Day range
- $1.22 – $1.55 USDNov 20, 2026
- Volume
- 3,802 sharesNov 20, 2026
- Market cap
- $2.58M USDAt the close on Nov 20, 2026 · price × 1.67M shares outstanding
- 52-week range
- $1.07 – $59.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $80,802 USDMedian day 9,597 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BCAB · Home | $1.55 USD | +0.26 (+20.2%) | 3,802 | $1.55 | $1.55 | $1.22 | $1.29 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BCAB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.55 | +0.26 | +20.2% | $1.55 | $1.55 | $1.22 | 3,802 | |
| $1.29 | -0.064 | -4.7% | $1.30 | $1.50 | $1.29 | 14,095 | |
| $1.354 | -0.446 | -24.8% | $1.52 | $1.528 | $1.28 | 12,756 | |
| $1.80 | -0.19 | -9.5% | $2.00 | $2.098 | $1.791 | 3,018 | |
| $1.99 | +0.43 | +27.6% | $1.79 | $2.01 | $1.762 | 9,562 | |
| $1.56 | -0.13 | -7.7% | $1.56 | $1.56 | $1.56 | 564 | |
| $1.69 | -0.16 | -8.6% | $1.55 | $1.70 | $1.52 | 1,518 | |
| $1.85 | +0.02 | +1.1% | $1.75 | $1.85 | $1.51 | 5,580 | |
| $1.83 | -0.26 | -12.4% | $2.00 | $2.00 | $1.54 | 13,147 | |
| $2.09 | +0.09 | +4.5% | $1.87 | $2.18 | $1.47 | 21,421 | |
| $2.00 | -0.09 | -4.3% | $1.65 | $2.061 | $1.60 | 6,400 | |
| $2.09 | +0.09 | +4.5% | $2.14 | $2.14 | $1.584 | 7,043 | |
| $2.00 | 0.00 | 0.0% | $1.903 | $2.00 | $1.86 | 5,224 | |
| $2.00 | -0.06 | -2.9% | $2.08 | $2.08 | $2.00 | 674 | |
| $2.06 | -0.04 | -1.9% | $2.11 | $2.11 | $2.06 | 1,009 | |
| $2.10 | 0.00 | 0.0% | $2.20 | $2.20 | $1.90 | 2,645 | |
| $2.10 | +0.10 | +5.0% | $1.59 | $2.10 | $1.59 | 1,002 | |
| $2.00 | -0.062 | -3.0% | $2.02 | $2.02 | $1.71 | 4,611 | |
| $2.062 | +0.102 | +5.2% | $1.95 | $2.074 | $1.638 | 28,320 | |
| $1.96 | +0.25 | +14.6% | $1.75 | $1.96 | $1.75 | 4,358 | |
| $1.71 | +0.48 | +39.0% | $1.40 | $1.76 | $1.40 | 7,323 | |
| $1.23 | -0.126 | -9.3% | $1.445 | $1.55 | $1.23 | 5,232 | |
| $1.356 | +0.026 | +2.0% | $1.34 | $1.50 | $1.34 | 3,617 | |
| $1.33 | +0.02 | +1.5% | $1.36 | $1.525 | $1.30 | 5,337 | |
| $1.31 | -0.05 | -3.7% | $1.22 | $1.31 | $1.22 | 2,183 | |
| $1.36 | +0.06 | +4.6% | $1.36 | $1.36 | $1.22 | 1,412 | |
| $1.30 | 0.00 | 0.0% | $1.30 | $1.30 | $1.29 | 3,283 | |
| $1.30 | +0.02 | +1.6% | $1.29 | $1.30 | $1.25 | 3,911 | |
| $1.28 | +0.03 | +2.4% | $1.28 | $1.28 | $1.27 | 11,852 | |
| $1.25 | -0.25 | -16.7% | $1.39 | $1.39 | $1.249 | 9,317 | |
| $1.50 | -0.05 | -3.2% | $1.55 | $1.57 | $1.34 | 2,906 | |
| $1.55 | -0.04 | -2.5% | $1.65 | $1.65 | $1.50 | 5,829 | |
| $1.59 | +0.24 | +17.8% | $1.23 | $1.59 | $1.23 | 10,118 | |
| $1.35 | +0.03 | +2.3% | $1.31 | $1.46 | $1.22 | 11,086 | |
| $1.32 | +0.01 | +0.8% | $1.31 | $1.32 | $1.23 | 1,390 | |
| $1.31 | +0.05 | +4.0% | $1.23 | $1.65 | $1.23 | 3,477 | |
| $1.26 | -0.04 | -3.1% | $1.45 | $1.45 | $1.26 | 3,495 | |
| $1.30 | -0.06 | -4.4% | $1.45 | $1.45 | $1.263 | 16,735 | |
| $1.36 | -0.16 | -10.5% | $1.55 | $1.65 | $1.36 | 6,530 | |
| $1.52 | +0.04 | +2.7% | $1.48 | $1.88 | $1.384 | 11,050 | |
| $1.48 | -0.04 | -2.6% | $1.31 | $1.48 | $1.17 | 10,813 | |
| $1.52 | -0.07 | -4.4% | $1.41 | $1.58 | $1.41 | 1,979 | |
| $1.59 | -0.18 | -10.2% | $1.75 | $1.78 | $1.31 | 35,105 | |
| $1.77 | -0.15 | -7.8% | $1.74 | $1.77 | $1.44 | 12,652 | |
| $1.92 | +0.13 | +7.3% | $1.71 | $2.03 | $1.41 | 21,983 | |
| $1.79 | -0.11 | -5.8% | $1.75 | $1.79 | $1.65 | 2,868 | |
| $1.90 | -0.50 | -20.8% | $2.50 | $2.50 | $1.40 | 73,927 | |
| $2.40 | +1.03 | +75.2% | $1.429 | $2.50 | $1.416 | 107,398 | |
| $1.37 | -0.10 | -6.8% | $1.50 | $1.52 | $1.34 | 9,632 | |
| $1.47 | -0.03 | -2.0% | $1.54 | $1.54 | $1.31 | 18,692 | |
| $1.50 | +0.32 | +27.1% | $1.27 | $1.55 | $1.10 | 27,727 | |
| $1.18 | -0.05 | -4.1% | $1.25 | $1.28 | $1.18 | 881 | |
| $1.23 | -0.03 | -2.4% | $1.30 | $1.45 | $1.18 | 14,900 | |
| $1.26 | -0.06 | -4.5% | $1.35 | $1.45 | $1.16 | 40,000 | |
| $1.32 | +0.02 | +1.5% | $1.25 | $1.39 | $1.16 | 19,100 | |
| $1.30 | +0.095 | +7.9% | $1.17 | $1.30 | $1.15 | 14,800 | |
| $1.205 | +0.125 | +11.6% | $1.08 | $1.40 | $1.08 | 20,300 | |
| $1.08 | -0.61 | -36.1% | $1.51 | $1.70 | $1.07 | 117,500 | |
| $1.69 | -0.045 | -2.6% | $1.76 | $2.13 | $1.31 | 130,200 | |
| $1.735 | -1.405 | -44.7% | $1.58 | $2.10 | $1.51 | 1,034,080 | |
| $3.14 | +0.02 | +0.6% | $3.15 | $3.245 | $3.07 | 31,334 | |
| $3.12 | -0.14 | -4.3% | $3.35 | $3.37 | $3.06 | 21,465 | |
| $3.26 | -0.02 | -0.6% | $3.28 | $3.47 | $3.09 | 55,312 | |
| $3.28 | +0.10 | +3.1% | $3.27 | $4.00 | $3.10 | 393,763 | |
| $3.18 | 0.00 | 0.0% | $3.26 | $3.41 | $3.03 | 88,744 | |
| $3.18 | -0.09 | -2.8% | $3.24 | $3.35 | $3.14 | 19,035 |
Splits
1 split · NASDAQ:BCAB · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-50 | Consolidation |
- Ticker
- BOATS:BCAB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Mar 31, 2026
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Latest deck · Mar 31, 2026
Investor Presentation (March 2026)
Investor deck · 82 slides
Latest news
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Mar 31, 2026
Closed $8.05 (+4.5%) on Mar 31, 2026
BioAtla Announces Share Consolidation
Mar 31, 2026
Closed $8.05 (+4.5%) on Mar 31, 2026
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
Mar 2, 2026
Closed $10.20 (-17.4%) on Mar 2, 2026
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Dec 31, 2025
Closed $28.40 (-20.8%) on Dec 31, 2025
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
Nov 21, 2025
Closed $43.45 (-25.1%) on Nov 21, 2025
BioAtla, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 4 in the last 12 months · 96 in all · newest Mar 31, 2026 · oldest 2020
- Calls
- 15 calls with a replay · 15 with a transcript · latest Nov 13, 2025
- Decks
- 11 decks · latest Mar 31, 2026
Where BioAtla, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BCAB · Home listing | NASDAQ | United States | USD |
| BOATS:BCAB · This page | BOATS | United States | USD |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.01M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- -0.34
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BioAtla, Inc. · NASDAQ:BCAB | US$2.58M | US$2.01M | n/a | n/a | n/a | n/a | n/a | n/a | -0.34 |
| Alligator Bioscience AB · OMXSTO:ATORX | US$2.79M | US$1.47M | n/a | 53.3× | n/a | 1.2× | n/a | 1.2× | n/a |
| Traws Pharma, Inc. · NASDAQ:TRAW | US$2.69M | US$351,448 | n/a | n/a | n/a | n/a | n/a | n/a | 2.07 |
| NextCell Pharma AB · OMXSTO:NXTCL | US$2.69M | US$626,140 | n/a | 0.6× | n/a | 0.6× | −440.8% | 0.0× | n/a |
| Bioxytran, Inc. · OTC:BIXT | US$2.66M | US$2.59M | n/a | n/a | n/a | n/a | n/a | n/a | -1.20 |
| Invion Ltd. · ASX:IVX | US$2.49M | US$3.12M | n/a | 12.2× | n/a | 0.7× | n/a | 0.3× | n/a |
| GRI Bio, Inc. · NASDAQ:GRI | US$2.45M | −US$6.99M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.89 |
| NeuroSense Therapeutics Ltd. · NASDAQ:NRSN | US$2.43M | US$2.20M | n/a | n/a | n/a | n/a | n/a | n/a | 1.41 |
| ValiRx PLC · LSE:VAL | US$2.42M | US$1.15M | n/a | 28.0× | n/a | 0.6× | n/a | 0.0× | n/a |
| BSF Enterprise PLC · LSE:BSFA | US$2.40M | US$2.95M | n/a | 42.7× | n/a | 1.0× | n/a | 0.3× | n/a |
| Revelation Biosciences, Inc. · NASDAQ:REVB | US$2.39M | −US$5.92M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 1.66 |
| Median of the others | US$2.47M | US$1.31M | 28.0× | 0.6× | −440.8% | 0.1× | 1.41 |
Forecasts
2 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 10.00 USD · Analysts' mean
- EPS, year to Dec 2025
- -1.38 · 3 analysts
Team and board
| Officer | Role |
|---|---|
| Richard Waldron | Chief Financial Officer |
Events
Calls
| Call | When | Status |
|---|---|---|
| BioAtla (NASDAQ:BCAB) Q3 2025 Earnings Call | Thu, Nov 13, 2025 · 4:30 PM ET | Replay |
| BioAtla (NASDAQ:BCAB) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| BioAtla (NASDAQ:BCAB) Q1 2025 Earnings Call | Tue, May 06, 2025 · 4:30 PM ET | Replay |
| BioAtla (NASDAQ:BCAB) Q4 2024 Earnings Call | Thu, Mar 27, 2025 · 4:30 PM ET | Replay |
| BioAtla (NASDAQ:BCAB) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 4:30 PM ET | Replay |
| BioAtla (NASDAQ:BCAB) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 4:30 PM ET | Replay |
| BioAtla (NASDAQ:BCAB) Q1 2024 Earnings Call | Tue, May 14, 2024 · 4:30 PM ET | Replay |
| BioAtla (NASDAQ:BCAB) Q4 2023 Earnings Call | Tue, Mar 26, 2024 · 4:30 PM ET | Replay |
| BioAtla (NASDAQ:BCAB) Q3 2023 Earnings Call | Tue, Nov 07, 2023 · 4:30 PM ET | Replay |
| BioAtla (NASDAQ:BCAB) Q2 2023 Earnings Call | Tue, Aug 01, 2023 · 4:30 PM ET | Replay |
All 15 calls
| Call | When | Status |
|---|---|---|
| BioAtla (NASDAQ:BCAB) Q1 2023 Earnings Call | Thu, May 11, 2023 · 4:30 PM ET | Replay |
| BioAtla (NASDAQ:BCAB) Q4 2022 Earnings Call | Thu, Mar 23, 2023 · 4:30 PM ET | Replay |
| BioAtla (NASDAQ:BCAB) Q3 2022 Earnings Call | Thu, Nov 03, 2022 · 4:30 PM ET | Replay |
| BioAtla (NASDAQ:BCAB) Q2 2022 Earnings Call | Tue, Aug 09, 2022 · 4:30 PM ET | Replay |
| BioAtla (NASDAQ:BCAB) Q1 2022 Earnings Call | Wed, May 04, 2022 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Aug 13, 2026 | −8.6% |
| Q1 2026 | May 29, 2026 | −12.8% |
| Q4 2025 | Mar 19, 2026 | +5.6% |
| Q3 2025 | Nov 13, 2025 · After close | +19.7% |
| Q2 2025 | Aug 7, 2025 · After close | −7.1% |
| Q1 2025 | May 6, 2025 · After close | −5.7% |
| Q4 2024 | Mar 24, 2025 · Before open | +5.4% |
| Q3 2024 | Nov 7, 2024 · After close | −5.4% |
| Q2 2024 | Aug 8, 2024 · After close | 0.0% |
| Q1 2024 | May 14, 2024 · After close | +14.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 26, 2024 · After close | +14.9% |
| Q3 2023 | Nov 7, 2023 · After close | −6.3% |
| Q2 2023 | Aug 1, 2023 · After close | +3.5% |
| Q1 2023 | May 11, 2023 · After close | +14.3% |
| Q4 2022 | Mar 23, 2023 · After close | +2.6% |
| Q3 2022 | Nov 4, 2022 · Before open | +18.7% |
| Q2 2022 | Aug 9, 2022 · After close | +83.1% |
| Q1 2022 | May 5, 2022 · After close | −9.2% |
| Q4 2021 | Mar 1, 2022 · Before open | −0.5% |
| Quarter to Sep 30, 2021 | Nov 15, 2021 · After close | +2.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2026) | Investor deck | 82 slides | Mar 31, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 70 slides | Nov 13, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 66 slides | May 6, 2025 |
| Investor Presentation (December 2024) | Investor deck | 49 slides | Dec 20, 2024 |
| Technical Presentation (October 2024) | Technical | 14 slides | Oct 11, 2024 |
| ESMO Sarcoma and Rare Cancers 2024 | Conference | 16 slides | March 2024 |
| Investor Presentation (January 2024) | Investor deck | 55 slides | Jan 9, 2024 |
| Technical Presentation (December 2023) | Technical | 8 slides | Dec 4, 2023 |
| AACR 2020 Virtual Annual Meeting II | Conference | 14 slides | February 2023 |
| Corporate Update (November 2022) | Corporate update | 11 slides | Nov 4, 2022 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Needham & Co Annual Healthcare Conference 2022 | Conference | 19 slides | Apr 11, 2022 |
Financings
| Raise | Date |
|---|---|
| Pre-paid advance convertible into common stock Closed: US$7.13M raised · Tungsten Advisors Dealers: Tungsten Advisors (lead) Buyers: Yorkville Advisors Global (affiliate) (part of an aggregate $7.5 million advance); Anson Advisors Inc. (funds managed by) (part of an aggregate $7.5 million advance) Use of proceeds: Support operations while finalizing a strategic partnership | Nov 21, 2025 |
| Common stock under Standby Equity Purchase Agreement Announced: Tungsten Advisors Dealers: Tungsten Advisors (lead) Buyers: Yorkville Advisors Global (affiliate) (commitment to buy up to a total of $15 million of common stock if the Company exercises its option) Use of proceeds: Support operations while finalizing a strategic partnership | Nov 21, 2025 |
| Registered direct offering of shares of common stock with accompanying warrants Announced: about US$9.2M · US$0.952 a share · Warrants at US$1.19 for 66 months · Tungsten Advisors (through its Broker-Dealer, Finalis Securities LLC) Dealers: Tungsten Advisors (through its Broker-Dealer, Finalis Securities LLC) (lead) Use of proceeds: Research and development including BA3182 and mecbotamab vedotin data readouts, partnering activities, working capital and general corporate purposes | Dec 20, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on Dec 15, 2020.
- Price
- US$18.00 a share
- Shares offered
- 10,500,000 shares of common stock
- Offering size
- US$189 million
- Underwriters' option
- Up to 1,575,000 more shares
- Underwriters
- J.P. Morgan, Jefferies, Credit Suisse, BTIG · In the order on the cover
- Shares delivered
- On or about Dec 18, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 6, 2020 |
| Filed publicly | Nov 13, 2020 |
| Amended twice | Newest Dec 9, 2020 |
| Shares registered with an exchange | Dec 9, 2020 |
| Declared effective by the SEC | Dec 15, 2020 |
| Final prospectus, with the price | Dec 17, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Dec 17, 2020 |
| EFFECT · Notice that a registration is effective | Dec 15, 2020 |
| S-1MEF · Registration of more shares for the same offering | Dec 15, 2020 |
| CERT · Exchange's certificate of listing | Dec 14, 2020 |
| CORRESP · Letter to the SEC | Dec 11, 2020 |
| CORRESP · Letter to the SEC | Dec 11, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Dec 9, 2020 |
| CORRESP · Letter to the SEC | Dec 9, 2020 |
| S-1/A · Registration statement, amended | Dec 9, 2020 |
| UPLOAD · Letter from the SEC | Dec 8, 2020 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Dec 8, 2020 |
| S-1/A · Registration statement, amended | Dec 8, 2020 |
| UPLOAD · Letter from the SEC | Dec 4, 2020 |
| CORRESP · Letter to the SEC | Nov 13, 2020 |
| S-1 · Registration statement | Nov 13, 2020 |
| UPLOAD · Letter from the SEC | Nov 4, 2020 |
| DRS · Draft registration statement | Oct 6, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Dec 17, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 300.0K | ||||||
| Research and development | 43.6M | 63.1M | 103.7M | 79.3M | 58.3M | 19.9M | 25.9M |
| Operating income | -59.3M | -73.9M | -129.7M | -108.1M | -96.4M | -30.1M | -28.3M |
| Depreciation and amortization | 373.0K | 925.0K | 1.22M | 1.20M | 1.33M | 1.01M | 860.0K |
| EBITDA | -58.9M | -73.0M | -128.5M | -106.9M | -95.1M | -29.1M | -27.4M |
| Interest expense | 0 | 3.00K | 1.39M | 1.63M | |||
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net income | -59.6M | -69.8M | -123.5M | -106.5M | -95.4M | -35.9M | -29.9M |
| Earnings per share, basic | -1.01 | -1.44 | -2.58 | -2.74 | -2.76 | -3.19 | |
| Earnings per share, diluted | -1.01 | -1.44 | -2.58 | -2.74 | -2.76 | -3.19 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.12M | 49.0M | 111.5M | 215.5M | 245.0M | 238.6M | 3.70M |
| Receivables | 0 | ||||||
| Current assets | 8.01M | 51.2M | 116.4M | 220.4M | 247.3M | 240.7M | |
| Property, plant and equipment | 120.0K | 678.0K | 1.60M | 2.73M | 3.68M | 4.10M | |
| Total assets | 13.8M | 52.4M | 119.7M | 225.7M | 254.4M | 244.9M | |
| Accounts payable | 8.19M | 1.90M | 3.82M | 4.23M | 1.18M | 2.46M | |
| Current liabilities | 21.9M | 14.5M | 28.3M | 23.1M | 19.8M | 32.3M | |
| Total liabilities | 50.0M | 38.2M | 49.0M | 45.4M | 43.6M | 35.0M | |
| Shareholders' equity | -36.2M | 14.3M | 70.7M | 180.3M | 210.8M | 210.0M | -56.0M |
| Shares outstanding | 1.27M | 58.1M | 48.1M | 46.3M | 35.8M | 32.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -48.2M | -71.9M | -104.0M | -90.4M | -62.2M | -36.3M | -9.64M |
| Cash from investing | 0 | -98.0K | -265.0K | -924.0K | -590.0K | -1.51M | |
| Cash from financing | 6.28M | 9.51M | 77.0K | 61.2M | 69.5M | 271.8M | 4.00M |
| Change in cash | -41.9M | -62.4M | -104.0M | -29.5M | 6.37M | 234.9M | -7.16M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Oct 30, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Oct 29, 2026 | Offer document | SEC |
| RW · Request to withdraw a registration | Oct 27, 2026 | Other filings | SEC |
| S-1 · Registration statement | Oct 19, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 19, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 29, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 28, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 16, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Jun 3, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jun 3, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jun 3, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2026 | Annual report | SEC |
| 8-K · Current report | Apr 2, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 31, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2026 | Results | SEC |
| 8-K · Current report | Mar 23, 2026 | Management or board change | SEC |
| 424B2 · Prospectus | Mar 20, 2026 | Offer document | SEC |
| 424B2 · Prospectus | Mar 13, 2026 | Offer document | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 424B2 · Prospectus | Mar 6, 2026 | Offer document | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Mar 2, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 2, 2026 | Results | SEC |
| DEFM14A | Feb 11, 2026 | Meeting notice | SEC |
| 8-K · Current report | Feb 9, 2026 | Current report | SEC |
| 8-K · Current report | Feb 6, 2026 | Current report | SEC |
| PREM14A | Jan 30, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 30, 2026 | Meeting outcome | SEC |
| S-3 · Registration statement | Jan 16, 2026 | Offer document | SEC |
| DEFA14A · Additional proxy material | Jan 15, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Dec 31, 2025 | Meeting notice | SEC |
| 8-K · Current report | Dec 31, 2025 | Material contract | SEC |
| 8-K · Current report | Dec 30, 2025 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Dec 5, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Nov 24, 2025 | Meeting notice | SEC |
| 424B5 · Prospectus | Nov 21, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 21, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 22, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 8-K · Current report | Jun 20, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 20, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 16, 2025 | Current report | SEC |
| 424B3 · Prospectus | May 16, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 15, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 12, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 9, 2025 | Other filings | SEC |
| S-3 · Registration statement | May 6, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 25, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 24, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 28, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 18, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Mar 14, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 7, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 24, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Dec 20, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 20, 2024 | Material contract | SEC |
| 8-K · Current report | Dec 20, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 2, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Sep 23, 2024 | Material contract | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Aug 7, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 8, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 8-K · Current report | May 17, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| 4 · Change in ownership | May 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 24, 2024 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 24, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2024 | Meeting notice | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 16, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 26, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 26, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 21, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 1, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jan 29, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 9, 2024 | Current report | SEC |
| 8-K · Current report | Jan 8, 2024 | Current report | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 13, 2023 | Current report | SEC |
| 8-K · Current report | Dec 4, 2023 | Current report | SEC |
| 4 · Change in ownership | Dec 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2023 | Results | SEC |
| 4 · Change in ownership | Nov 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2023 | Insider trade | SEC |
This page holds 200 of 510 filings. Open Filings
Cap table
Built by 6ix from BioAtla, Inc.’s releases · as of Nov 21, 2025
- Common shares
- 1,666,100
- Fully diluted
- 1,666,100
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,666,100 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,666,100 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Mary Ann Gray Other companies: Keros Therapeutics, Inc. (Director · Since at least Jun 1, 2022); Compass Therapeutics, Inc. (Director · Since at least Apr 26, 2022); RAPT Therapeutics Inc (Director · Since at least Mar 31, 2022); Palisade Bio, Inc. (Director · Jun 11, 2023 – Nov 21, 2023 · Past) | Director · Since at least Jun 16, 2022 |
| Susan Moran Other companies: Crescent Biopharma, Inc. (Director · Since at least Jun 13, 2025); Tyra Biosciences, Inc. (Board member · Since at least May 7, 2024); RayzeBio, Inc. (CHIEF MEDICAL OFFICER · Sep 14, 2023 – Feb 26, 2024 · Past) | Director · Since at least Dec 15, 2020 |
| Eddie Williams Other companies: BiomX Inc. (Director · Oct 12, 2023 – Apr 14, 2025 · Past); Gyre Therapeutics, Inc. (Director · Jan 2, 2018 – Jan 7, 2022 · Past) | Director · Since at least Dec 16, 2021 |
| Lawrence Steinman Other companies: Pasithea Therapeutics Corp. (Director · Since at least Sep 14, 2021); Forum Markets, Incorporated (Director · Since at least Nov 6, 2020) | Director · Since at least Dec 15, 2020 |
| Scott A. Smith Other companies: Viatris Inc. (Chief Executive Officer, Director · Since at least Dec 29, 2022); Apexigen Inc. (Director · Jul 29, 2022 – Aug 23, 2023 · Past) | Director · Since at least Mar 31, 2022 |
| Jay M Phd Short Other companies: Senomyx Inc (Director · May 24, 2006 – May 20, 2016 · Past) | Chief Executive Officer, Director · Since at least Dec 15, 2020 |
| Priyanka Belawat Other companies: Iteos Therapeutics Inc (Director · Jul 23, 2020 – Jul 23, 2020 · Past) | Director · Dec 15, 2020 – Dec 15, 2020 · Past |
| Carolyn Anderson Short | See Remarks · Dec 15, 2020 – Dec 15, 2020 · Past |
| Christian Vasquez | Chief Financial Officer · Since at least Dec 15, 2020 |
| Eric Sievers | Chief Medical Officer · Since at least Dec 15, 2020 |
All 12 people
| Person | Seat |
|---|---|
| Richard Waldron | Chief Financial Officer · Since at least Dec 15, 2020 |
| Sylvia McBrinn | Director · Since at least Jun 15, 2021 |
Log in to ask 6ix AI your own questions about BioAtla, Inc.